key: cord-0776958-dw3ug4pe authors: CS, Lau; SP, Hoo; YL, Liang; SK, Phua; TC, Aw title: PERFORMANCE OF TWO RAPID POINT OF CARE SARS-COV-2 ANTIBODY ASSAYS AGAINST LABORATORY-BASED AUTOMATED CHEMILUMINESCENT IMMUNOASSAYS FOR SARS-COV-2 IG-G, IG-M AND TOTAL ANTIBODIES date: 2021-01-19 journal: Pract Lab Med DOI: 10.1016/j.plabm.2021.e00201 sha: e2c4645f0d44d8720faacb079c13ac3d582faed7 doc_id: 776958 cord_uid: dw3ug4pe INTRODUCTION: We evaluated two SARS-CoV-2 antibody point-of-care tests (POCTs) (Abbott Panbio COVID-19 IgG/IgM and Roche SARS-CoV-2 Rapid Antibody tests) and compared the results to their respective chemiluminescent immunoassays (CLIAs) (Abbott Architect IgM, Architect IgG, Roche Cobas total antibody assays). METHOD: 200 pre-pandemic sera and 48 samples positive for various conditions (18 viral hepatitis, 18 dengue, 11 ANA and 1 dsDNA) were used as controls and to assess for cross-reactivity. Anonymised residual leftover sera positive for SARS-CoV-2 on RT-PCR were recruited as cases (n=133). The sensitivity/specificity/cross-reactivity/positive predictive value (PPV)/negative predictive value (NPV) of the POCTs were assessed. Concordance between the POCTs and chemiluminescent immunoassays (CLIAs) were analysed. RESULTS: Abbott/Roche POCT specificity was 98.7%/100% (95% CI 96.5-99.8/98.5-100) and sensitivity was 97.2%/97.2% (95% CI 85.5-99.9/85.5-99.9) in cases ≥14 days post-first positive RT-PCR (POS), PPV was 68.7%/100% (95% CI 41.3-87.2/94.7-100.0), and NPV was 97.4%/97.6% (95% CI 97.0-97.8/97.2-98.0). In cases ≥14 days POS, concordance of Abbott/Roche POCT and CLIAs was 97.2%/100% (35/36 and 36/36 results). The sensitivity of individual IgM-band results on both POCTs did not increase >95% even after 14 days POS (Abbott 2.78%, Roche 44.4%). CONCLUSION: Both POCTs have good specificity, little cross-reactivity with other antibodies, and sensitivity >95% when used in subjects ≥14 days POS. Analysis of individual POCT IgG/IgM-bands did not provide any additional information. POCTs can substitute for CLIAs in cases ≥14 days POS. In low prevalence areas, POCTs would be especially useful when combined with antigen testing in an orthogonal format to increase the PPV of COVID-19 results. Current novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody result. For both POCTs, a sample is considered as reactive if either IgG and/or IgM bands 1 are positive. Both assays require a 10-minute reaction time followed by a read time between 2 10-20 minutes (Abbott) and 10-15 minutes (Roche); results beyond 20 minutes were 3 For RT-PCR testing, our hospital molecular laboratory employs a duplex real-time RT-PCR 5 that targets the N and E genes using a Qiagen EZ1 extraction system and Rotor Gene Q 6 amplification system. The Abbott Architect SARS-CoV-2 IgG assay is a qualitative CLIA run 7 on the ARCHITECT i2000 System, as described previously [1] . The stated cut-off index 8 (COI) of the Architect IgG assay is 1.4. In our hands [1] , the Architect IgG assay had a CV of 9 3.4% (COI=0.06) and 1.6% (COI=8.6); assay specificity was 99.8%, and sensitivity of 96.7% 10 for samples ≥14 days POS and 45.9% for samples <7 days. The Architect SARS-CoV-2 11 IgM antibody assay is also a CLIA that uses a similar principle to the Architect IgG assay, 12 resulting in a signal (relative light unit) that is directly proportional to the amount of SARS-13 CoV-2 IgM titres and reflected in a COI; a COI of >1.0 is regarded as reactive. The 14 manufacturer reported precision of the assay is 2.8/2.9% (COI of 1.96/2.80), with a reported 15 sensitivity of 59.5% (0-7 days POS) to 100% (>14 days POS) and a specificity of 99.7%. The 16 Roche SARS-CoV-2 total antibody assay is also a CLIA and has been described previously 17 [2]. It has a stated COI of 1.0, and in our hands, CV was 2.9% (COI=0.1) and 5 Table 1 ); both of these samples were non-reactive on the Architect IgG and IgM assays 6 (COI <0.03 for both). All dengue cases (n=18) were not reactive on both POCT assays. Out 7 of 248 non-reactive controls, two cross-reactivity samples were positive on the IgM-band, 8 and one pre-pandemic HS sample was IgG positive on the Abbott POCT, and none were 9 reactive on the Roche POCT (see Table 1 ). This yielded a specificity of 98.7% (95% CI 96.5 10 to 99.8) on the Abbott POCT, and a specificity of 100% (95% CI 98.5 to 100) on the Roche 11 POCT. Concordance between the Abbott POCT and Abbott CLIA was 98.8%, and 12 concordance between the Roche POCT and Roche CLIA was 100% 13 performance subsequently improved to >95% for all assays after 14 days POS (see Table 2 8 and 3). The POCT assays agreed closely with the CLIA results after 14 days POS (Abbott 9 97.2% concordance, Roche 100% concordance). 10 As there appeared to be difference in the results from 0-6 days POS, we performed 11 McNemar testing between the POCT and CLIA in these cases. There was a significant 12 difference in the sensitivities between the Abbott POCT and Architect IgM and IgG results 13 (20%, 95% CI 10.3 to 29.7, p = 0.0002), but not between the Roche POCT and Cobas total 14 antibody results (3.08%, 95% CI -8.18 to 14.3, p = 0.79). There was a significant difference 15 in sensitivity between the Architect and Cobas results (15.4%, 95% CI 2.43 to 28.3, p = 16 0.04), but not between the Abbott and Roche POCTs (7.69%, 95% CI -0.06 to 15.5, p = 17 0.13). 18 week of infection (0.00%), which did not improve much even after 2 weeks (PPA 2.78% 2 (95% CI 0.07 to 14.5) ≥14 days POS), with a total sensitivity of 3.01% (95% CI 0.83 to 7.52) 3 (see Supplementary Table 2 ). The IgM-band on the Roche POCT had a higher sensitivity 4 (7.69% in the first week, 46.9% 7 to 13 days POS), but also did not increase to >95% after 5 the second week (44.4%) (see Supplementary Table 3) . It is essential that the performance of newly developed POCT assays be thoroughly 6 evaluated before use. Performance between different POCT assays varies greatly (see 7 Supplementary Table 4 ) [5] [6] [7] [8] [9] [10] [11] [12] with a range of different assay sensitivities. The meta-8 analysis by ML Bastos in July 2020 [3] showed that POCT assays up till April 2020 had 9 varied sensitivities (36.4% to 100%). LFIAs since then continue to have sensitivities that can 10 range from 22% to 60.9% [11, 12] . Therefore, the recent IFCC guidelines [13] on serological 11 testing for SARS-CoV-2 recommends follow up with a laboratory assay for patients with a 12 high suspicion of infection even when negative POCT results are encountered. 13 Up to 40-45% of COVID-19 infections may be asymptomatic [14] . SARS-CoV-2 RT-PCR 14 only has a sensitivity of around 79% [15] , with a false-negative rate of 38% on the day of 15 disease onset [16] . Indeed, in a study of 164 close contacts of known COVID-19 cases [ shows that sensitivity increases appreciably to 91-94% only 14 days after disease onset. 6 CLIAs have the advantage in that they diagnose reactivity based on a reportable COI value. 7 In our previous evaluation of the Abbott Architect IgG assay with a larger study population 8 [1] , an initial sensitivity of 45.9% within the first week of infection could be improved to 55.8% 9 by using a lower, optimized COI value for reactivity. Other studies [24] have also suggested 10 that a lower COI value for the diagnosis of reactive samples will improve the sensitivity of 11 CLIAs in their cases with early infection. However, POCTs do not have the ability to report 12 COIs, and thus cannot benefit from this modification to improve sensitivities. IgM components on POCTs for test interpretation. One study that examined the kinetics of 17 SARS-CoV-2 antibodies in COVID-19 infections [25] has shown that IgM does increase in 18 the first week after symptom onset (seropositivity rate of 75%), but this elevation becomes 19 blunted by the second week of infection (IgM seropositivity increasing to 84.2%, IgG to 20 94.7%) and declines thereafter. A study of 285 patients [17] showed that the seroconversion 21 of IgG and IgM may occur either simultaneously or sequentially. In another study [26] In the review by Bastos et al [3] , the pooled sensitivity of LFIAs was 49.3-79.3%, with a 26 pooled specificity of 94.3-98.2%. Several SARS-CoV-2 antigen tests have been given EUAs by the FDA [28], for example the Abbott BinaxNow (reported sensitivity 97.1%, specificity 1 98.5%) [29] . A recent Cochrane review of antigen tests showed a pooled sensitivity of 56.2% 2 and specificity of 99.5% [30] . PPVs of LFIAs may be acceptable in an optimized laboratory-3 based evaluation. However, their performance in the real world will be impaired especially in 4 low prevalence areas. This limitation can be improved when one test is combined with 5 another test (e.g. antigen test) in an orthogonal approach [18] . To investigate this orthogonal 6 effect, we have used the online calculator provided by the FDA to estimate the combined 7 performance of two independent tests [31] . Assuming a population prevalence of 5%, and 8 pooled sensitivities/specificities of the antigen test (sensitivity 56.2%, specificity 99.5%) and 9 LFIAs (sensitivity 49.3-79.3%, specificity 94.3-98.2%) in an orthogonal test format (a positive 10 antigen test followed by an antibody test), the combined PPV would be better than the PPV 11 of each individual test alone (see Table 4 ). 12 13 The strengths of our study are that we have assessed the cross-reactivity of the assay with 10 commonly found antibody positive cases in other disorders. We have also assessed the 11 sensitivity performance, and concordance with CLIAs, of two newly released POCTs 12 stratified by days POS (0-6/7-13/≥14). Some studies [33] have shown that dengue infections 13 can lead to some false positive cases on other assays. Within our study, dengue antibodies 14 have no cross-reactivity with both POCTs. 15 We report the following findings for both POCTs: 16 The IgM-band is negative in most cases of COVID-19. There is little utility in examining the IgG-IgM bands individually. 21 The sensitivity of the POCTs only improves greatly after 14 days POS. 22 Combining the antibody test with another test (e.g. a SARS-CoV-2 antigen assay) in 23 orthogonal testing can greatly improve the PPV of both assays. 24 We have provided a compilation of recently evaluated LFIAs for COVID-19 (see 25 Supplementary Table 4 ) for the benefit of readers. 1 blood/fingerstick samples more commonly used in POCT situations. Matrix influence can 2 significantly affect POCT results; some studies [11] suggest that for some LFIA assays, 3 serum samples can result in a higher sensitivity than finger prick samples (80% sensitivity vs 4 22% sensitivity). In all other situations for POCTs, the difference between whole 5 blood/fingerstick versus serum is less than the relative change value. Indeed, since 6 submission we had 2 new cases of COVID-19 in our institution, and on testing with all 3 7 matrixes there was complete agreement on the POCTs. The population of this study was a 8 hospital population, and in the general population, antibody responses might be lower due to 9 a higher number of asymptomatic/pauci-symptomatic infections [12, 34, 35] . More severe 10 infections have higher antibody titres than less severe cases. When serial blood samples in 11 38 patients with severe COVID-19 was compared to 24 mild COVID-19 infections [36], 65% 12 of severe cases demonstrated antibody activity, compared to 30% in mild cases. Liu et al 13 [27] showed a significant difference in the IgG response between patients with mild and 14 severe infection. In some mild cases (21.43%), an adequate level of IgG antibodies did not 15 develop until 9 days after symptom onset. Weaker antibody responses can cause 16 negative/borderline POCT results. In a study evaluating seven LFIAs [12] , patients with 17 lower IgM levels were more prone to produce borderline results on POCT testing; they found 18 6 asymptomatic RT-PCR positive COVID-19 patients who had repeated negative LFIA 19 results. The sensitivities of the Architect and Cobas CLIAs are also different from our 20 previous evaluations [1, 2] . This is because the populations used in the previous studies 21 were larger and had different demographics. Further evaluations of both POCTs using larger 22 populations would be desirable. We would like to thank Abbott Diagnostics, Singapore, and Roche Diagnostics, Singapore, 15 for providing the test kits used in this study. Both had no role in the design, conduct, or 16 manuscript writing of this study. Performance of an automated 8 chemiluminescence SARS-COV-2 IG-G Assay Evaluation of an 11 electrochemiluminescent SARS-CoV-2 antibody assay Diagnostic accuracy of serological tests for covid-19: systematic review and meta-15 analysis US Food and Drug Administration, Emergency Use Authorization Authorization (EUA) information, and list of all current EUAs Serological 22 immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 23 patients Prevalence of Asymptomatic SARS-CoV-2 Infection, A Narrative 4 Diagnostic performance 7 between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus 8 disease (COVID-19) patients outside Wuhan, China Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS CoV-2 Tests by Time Since Exposure SARS-CoV-2 in patients with COVID-19 A systematic review of antibody mediated immunity to coronaviruses: 22 kinetics, correlates of protection, and association with severity Doi: et al, Humoral Immune Response to SARS-CoV-2 in Iceland biochemical diagnosis and monitoring of COVID-19: IFCC taskforce 5 evaluation of the latest evidence Evaluation of two automated and three rapid lateral flow immunoassays for the detection 8 of anti-SARS-CoV-2 antibodies Clinical 10 performance of the Elecsys electrochemiluminescent immunoassay for the detection of 11 SARS-CoV-2 total antibodies Kinetics of SARS-CoV specific IgM and IgG responses in COVID-19 patients Seroprevalence of immunoglobulin SARS-CoV-2 in China Patterns of IgG and IgM antibody 19 response in COVID-19 patients US Food and Drug Administration, BinaxNOWTM COVID-19 Ag CARD 27 point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection Rethinking Covid-19 Test Sensitivity -A Strategy 7 for Containment Potential 10 antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses Distinct features of SARS CoV-2-specific IgA response in COVID-19 patients Clinical and immunological 17 assessment of asymptomatic SARS-CoV-2 infections Acute Respiratory Syndrome Coronavirus 2 Infections ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: NA J o u r n a l P r e -p r o o f